Online inquiry

IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15952MR)

This product GTTS-WQ15952MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15952MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3312MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ10553MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ13410MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ5568MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ13094MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ5182MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ12180MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ15087MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW